Adverse drug reaction to tremelimumab and durvalumab in hepatocellular carcinoma patients: an analysis of the food and drug administration adverse event reporting system database

Adverse drug reaction to tremelimumab and durvalumab in hepatocellular carcinoma patients: an analysis of the food and drug administration adverse event reporting system database

Abstract Objective This study sought to comprehensively evaluate the safety profile of tremelimumab and durvalumab in patients with hepatocellular carcinoma (HCC) by examining adverse drug reaction (ADR) documented in the Food and Drug Administration’s Adverse Event Reporting System (FAERS) database...

Full description

Saved in:
Bibliographic Details
Main Authors: Wei Fan Sui, Yu Xin Duan, Ze Feng Cai, Yi Mao Xia, Jian Yun Li, Jian Hua Fu
Format: Article
Language:English
Published: BMC 2025-08-01
Series:BMC Cancer
Subjects:
Adverse drug reactions
Tremelimumab
Durvalumab
FAERS
Hepatocellular carcinoma
Online Access:https://doi.org/10.1186/s12885-025-14696-7
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12885-025-14696-7

Similar Items